Neoantigens can be used to develop personalized therapeutic cancer vaccines that teach the patient's immune system to recognize and kill cancer cells. The NEC Neoantigen Prediction Pipeline uses bioinformatics and machine learning to analyze the DNA and RNA of cancer patients to identify neoantigens originating from cancer mutations. NEC Laboratories Europe was a key contributor in developing the prediction pipeline, providing machine learning algorithms for the system, which is being used by NEC biotech partners for the research and development of immunotherapy.
The prerequisite for destroying cancer is the binding of T cell receptors to neoantigens on the surface of cancer cells. NEC Laboratories Europe, in collaboration with NEC Laboratories America, developed the AI model, Attentive Variational Information Bottleneck (AVIB). AVIB represents a first step towards predicting the likelihood that T cell receptors will recognize certain neoantigens. For cancer immunotherapy, this allows biotechnologists to select neoantigens that have a high chance of being recognized by the patient’s immune system, which increases vaccine efficiency.